IROX as second-line therapy for metastatic colorectal cancer

被引：0
|
作者：
Alberto Sobrero
机构：
[1] Ospedale San Martino,
来源：
Nature Reviews Clinical Oncology | 2009年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Haller et al. demonstrated that irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in advanced colorectal cancer. IROX does not change, but enriches the treatment algorithm of advanced colorectal cancer at the second-line level.
引用
收藏
页码：248 / 250
页数：2
相关论文
共 50 条
  • [31] Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?
    Giampieri, Riccardo
    Caporale, Marta
    Pietrantonio, Filippo
    De Braud, Filippo
    Negri, Francesca V.
    Giuliani, Francesco
    Pusceddu, Valeria
    Demurtas, Laura
    Restivo, Angelo
    Fontanella, Caterina
    Aprile, Giuseppe
    Cascinu, Stefano
    Scartozzi, Mario
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 : 99 - 106
  • [32] Evaluation of safety of bevacizumab as second-line treatment of patients with metastatic colorectal cancer
    Todorovic, Vladimir
    Saric, Nada Cicmil
    Lakicevic, Jadranka
    Sorat, Milan
    JOURNAL OF BUON, 2017, 22 (05): : 1131 - 1136
  • [33] Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience
    Raquel Claramunt García
    Carmen Lucía Muñoz Cid
    Andrés Sánchez Ruiz
    Juan Francisco Marín Pozo
    European Journal of Clinical Pharmacology, 2022, 78 : 287 - 291
  • [34] Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience
    Claramunt Garcia, Raquel
    Munoz Cid, Carmen Lucia
    Sanchez Ruiz, Andres
    Marin Pozo, Juan Francisco
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (02) : 287 - 291
  • [35] Second-line treatment in older patients with metastatic colorectal cancer: The ELECTRA study
    Cordua, A.
    Basile, D.
    Sperotto, S.
    Foltran, L.
    Casagrande, M.
    Carullo, M.
    Morano, F.
    Lucchetti, J.
    Rosati, G.
    Avallone, A.
    Lai, E.
    Lutrino, E. S.
    Parnofiello, A.
    Guardascione, M.
    Leone, A. G.
    Zurlo, I. V.
    Conca, V.
    Leo, S.
    Lonardi, S.
    Aprile, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S448 - S448
  • [36] Evaluation of systemic second-line therapy in recurrent or metastatic esophageal cancer
    Bacinschi, Xenia E.
    Zgura, Anca
    Stanuica, Monica, I
    Iliescu, Laura
    Anghel, Rodica M.
    ROMANIAN JOURNAL OF MILITARY MEDICINE, 2021, 124 (02) : 203 - 210
  • [37] Second-Line Therapy in metastatic castration refractory Prostate Cancer (mCRPC)
    Rexer, H.
    Graefen, M.
    Merseburger, A.
    UROLOGE, 2019, 58 (03): : 359 - 360
  • [38] Second-line systemic therapy for the treatment of metastatic renal cell cancer
    Kruck, Stephan
    Bedke, Jens
    Kuczyk, Markus A.
    Merseburger, Axel S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (06) : 777 - 785
  • [39] Second-line therapy for advanced colorectal carcinoma
    Starling N.
    Cunningham D.
    Current Oncology Reports, 2005, 7 (3) : 173 - 180
  • [40] Irinotecan - Clinical progress in the second-line therapy of advanced colorectal cancer
    Bokemeyer, C
    ONKOLOGIE, 2000, 23 : 28 - 31
12345